Cabozantinib
Carcinoid Tumor
Floatz Rating
B57/100
Confidence
Indicative
Sponsor
Fox Chase Cancer Center
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05263050CT.gov Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors | — | Recruiting | — | — | — |
NCT01466036CT.gov Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Carcinoid Tumor
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cabozantinib (this asset) | Fox Chase Cancer Center | P2 | B · 57 |
| Paltusotine | Crinetics Pharmaceuticals Inc. | P3 | BB |
| Oxodotreotide | RayzeBio, Inc. | P3 | BB |
| Everolimus | RayzeBio, Inc. | P3 | B |
| L-Cysteinamide, D-Phenylalanyl-L-Cysteinyl-L-Phenylalanyl-D-Tryptophyl-L-Lysyl-L-Threonyl-N-(2-Hydroxy-1-(Hydroxymethyl)Propyl)-, Cyclic (2->7)-Disulfide, (R-(R*,R*))- | RayzeBio, Inc. | P3 | B |
| Lanreotide | RayzeBio, Inc. | P3 | B |
| Edotreotide | British Columbia Cancer Agency | P2 | B |
| Pasireotide | H. Lee Moffitt Cancer Center and Research Institute | P2 | B |
| Axitinib | H. Lee Moffitt Cancer Center and Research Institute | P2 | B |
+18 more in the Carcinoid Tumor cohort
Other indications for Cabozantinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Renal Carcinoma | — | P4 | BB · 70 |
| Castration-Resistant Prostate Carcinoma | — | P3 | BB · 70 |
| Kidney Cancer | — | P4 | BB · 66 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Cabozantinib in Carcinoid Tumor. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/cabozantinib-carcinoid-tumor
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →